Search - Institut Paoli-Calmettes Access content directly

Filter your results

296 Results
Deposit type : Notice

Etude de phase II sur l’efficacité et la tolérance d’une augmentation de dose de radiothérapie des lésions hypoxiques définies par TEP-scanographie au fluoromisonidazole chez les patients suivis pour un cancer bronchique non à petites cellules

Sébastien Thureau , Philippe Chaumet Riffaud , Romain Modzelewski , Sébastien Hapdey , Marc Mahé , et al.
Congrès de la Société Française de Radiothérapie et Oncologie, 2016, Paris, France
Conference poster hal-01665300v1

Characterisation of heterozygous PMS2 variants in French patients with Lynch syndrome

Qing Wang , Julie Leclerc , Gaëlle Bougeard , Sylviane Olschwang , Stéphanie Vasseur , et al.
Journal of Medical Genetics, 2020, pp.jmedgenet-2019-106256. ⟨10.1136/jmedgenet-2019-106256⟩
Journal articles hal-02460716v1

Performance of CT Compared with F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma

Fatima-Zohra Mokrane , Aiping Chen , Lawrence H Schwartz , Franck Morschhauser , Apasia Stamatoullas , et al.
Radiology, 2020, 295 (3), pp.651-661. ⟨10.1148/radiol.2020192056⟩
Journal articles hal-02569415v1

French ccAFU guidelines - Update 2018-2020 Prostate cancer

F. Rozet , C. Hennequin , J-B Beauval , P. Beuzeboc , L. Cormier , et al.
Progrès en Urologie, 2018, 28 (12), pp.S79-S130. ⟨10.1016/j.purol.2018.08.001⟩
Journal articles hal-01978475v1

Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells

Amélie Fouqué , Olivier Delalande , Mickael Jean , Rémy Castellano , Emmanuelle Josselin , et al.
Journal of Medicinal Chemistry, 2019, 62 (20), pp.9339-9340. ⟨10.1021/acs.jmedchem.9b01578⟩
Journal articles hal-02526957v1

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Emilie Reboursiere , Fabien Le Bras , Charles Herbaux , Emmanuel Gyan , Aline Clavert , et al.
Oncotarget, 2016, 7 (51), pp.85573-85583. ⟨10.18632/oncotarget.10764⟩
Journal articles hal-01475957v1

Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate

F. Rozet , C. Hennequin , J.-B. Beauval , P. Beuzeboc , L. Cormier , et al.
Progrès en Urologie, 2019, 28, pp.R81-R132. ⟨10.1016/j.purol.2019.01.007⟩
Journal articles hal-02281703v1

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

P. Rodon , C. Hulin , B. Pegourie , M. Tiab , B. Anglaret , et al.
Haematologica, 2015, 100 (2), pp.e56-9. ⟨10.3324/haematol.2014.110890⟩
Journal articles hal-01116536v1

Impact of body mass index on overall survival in patients with metastatic breast cancer

Khalil Saleh , Matthieu Carton , Véronique Dieras , Pierre-Etienne Heudel , Etienne Brain , et al.
Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩
Journal articles hal-03345238v1

Les points chauds de l’actualité en 2017. Une sélection du comité de rédaction du Bulletin du Cancer

Stéphane Vignot , Thierry André , Christophe Caux , Carole Bouleuc , Serge Evrard , et al.
Bulletin du Cancer, 2018, 105 (1), pp.6 - 14. ⟨10.1016/j.bulcan.2017.11.006⟩
Journal articles hal-01712424v1

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Cédric Rossi , Julia Gilhodes , Marie Maerevoet , Charles Herbaux , Franck Morschhauser , et al.
American Journal of Hematology, 2018, 93 (8), pp.1042-1049. ⟨10.1002/ajh.25154⟩
Journal articles hal-02050402v1

Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)

Jérémie H. Lefevre , Laurent Mineur , Salma Kotti , Eric Rullier , Philippe Rouanet , et al.
Journal of Clinical Oncology, 2016, 34 (31), pp.3773 - 3780. ⟨10.1200/JCO.2016.67.6049⟩
Journal articles hal-01903754v1

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

Nicolas Penel , Olivier Mir , Jennifer Wallet , Isabelle Ray-Coquard , Axel Le Cesne , et al.
European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩
Journal articles hal-03623680v1

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)

Cindy Neuzillet , Sebastien Gaujoux , Nicolas Williet , Jean-Baptiste Bachet , Lucile Bauguion , et al.
Digestive and Liver Disease, 2018, 50 (12), pp.1257-1271. ⟨10.1016/j.dld.2018.08.008⟩
Journal articles hal-02143547v1

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.

Camille Laurent , Alina Nicolae , Cecile Laurent , Fabien Le Bras , Corinne Haioun , et al.
Blood, 2019, 135 (5), pp.360-370. ⟨10.1182/blood.2019001904⟩
Journal articles hal-02529694v1

Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie

Ronan Flippot , Christophe Massard , Édouard Auclin , David Azria , Heloise Bourien , et al.
Bulletin du Cancer, 2017, 104 (9), pp.735-743. ⟨10.1016/j.bulcan.2017.07.003⟩
Journal articles hal-02370054v1

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Damien Pouessel , Sylvie Chevret , Frédéric Rolland , Gwenaëlle Gravis , Lionel Geoffrois , et al.
European Journal of Cancer, 2016, 54, pp.69--74. ⟨10.1016/j.ejca.2015.11.017⟩
Journal articles hal-01278607v1

Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study

Luis Paz-Ares , Adam Gondos , Diego Saldana , Marlene Thomas , Céline Mascaux , et al.
LUNG CANCER, 2022, 167, pp.41-48. ⟨10.1016/j.lungcan.2022.01.021⟩
Journal articles hal-04085318v1

Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

K. S. Saini , I. M. Svane , M. Juan , F. Barlesi , F. Andre
Annals of Oncology, 2022, 33 (1), pp.6-12. ⟨10.1016/j.annonc.2021.09.020⟩
Journal articles hal-04085346v1

Preparation of thiophenepropenamide derivatives as flavivirus inhibitors in treatment of viral infections

Karine Barral , Jean Claude Guillemot , Bruno Canard , Gilles Quérat , Karine Alvarez , et al.
France, Patent n° : WO 2017102014. 2017
Patents hal-02063286v1

Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis

Mélanie Velier , Aurélie Daumas , Stéphanie Simoncini , Robin Arcani , Jérémy Magalon , et al.
Bone Marrow Transplantation, 2022, 57 (1), pp.17-22. ⟨10.1038/s41409-021-01492-7⟩
Journal articles hal-03777104v1

PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

François Bertucci , Pascal Finetti , Delphine Perrot , Agnès Leroux , Françoise Collin , et al.
OncoImmunology, 2017, 6 (3), pp.e1278100. ⟨10.1080/2162402X.2016.1278100⟩
Journal articles hal-01765418v1

Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing

Dede Sika Kossi , Rajae Touzani , Isabelle Borget , Zhaomin Zou , Dominique Vaur , et al.
ISPOR 19th Annual European Congress, Oct 2016, Vienne, Austria. pp.A693
Conference papers halshs-01446644v1

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer

C. Bascoul-Mollevi , S. Gourgou , M.-P. Galais , J.-L. Raoul , O. Bouche , et al.
European Journal of Cancer, 2017, 84, pp.239 - 249. ⟨10.1016/j.ejca.2017.07.038⟩
Journal articles hal-01688845v1

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Stéphane Culine , Valentin Harter , Gwenaelle Gravis , Aude Fléchon , Christine Chevreau , et al.
Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩
Journal articles hal-03625944v1

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

J.E. Martin , S. Khalife-Hachem , T. Grinda , M. Kfoury , S. Garciaz , et al.
Annals of Oncology, 2021, 32 (8), pp.1046-1048. ⟨10.1016/j.annonc.2021.04.015⟩
Journal articles hal-03623367v1

[2021 update of the GEFPICS’ recommendations for HER2 status assessment in invasive breast cancer in France]

Camille Franchet , Lounes Djerroudi , Aurélie Maran-Gonzalez , Olivia Abramovici , Martine Antoine , et al.
Annales de Pathologie, 2021, ⟨10.1016/j.annpat.2021.07.014⟩
Journal articles hal-03333764v1

Functional status in older patients with cancer

Anne-Laure Couderc , Pierre Suchon , Bérengère Saliba-Serre , Dominique Rey , Emilie Nouguerede , et al.
Journal of Geriatric Oncology, 2022, 13 (1), pp.40-45. ⟨10.1016/j.jgo.2021.07.004⟩
Journal articles hal-03585184v1

Functional status in older patients with lung cancer: an observational cohort study

Anne-Laure Couderc , Pascale Tomasini , Laurent Greillier , Emilie Nouguerède , Dominique Rey , et al.
Supportive Care in Cancer, 2022, 30 (5), pp.3817-3827. ⟨10.1007/s00520-021-06752-2⟩
Journal articles hal-03585187v1

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

François Bertucci , Anthony Gonçalves , Arnaud Guille , José Adelaïde , Séverine Garnier , et al.
Genome Medicine, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩
Journal articles hal-03583277v1